Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study

Adele Salemme¹, Luca Fania², Alessandra Scarabello³, Marzia Caproni⁴, Angelo Valerio Marzano⁵, Emanuele Cozzani⁶, Claudio Feliciani⁷, Clara De Simone⁸, Manuela Papini⁹, Rosanna Rita Satta¹⁰, Aurora Parodi⁶, Feliciana Mariotti¹, Stefania Lechiancole², Giovanni Genovese⁵, Francesca Passarelli¹¹, Francesca Festa², Barbara Bellei¹², Alessia Provini², Donatella Sordi², Sabatino Pallotta¹³, Damiano Abeni¹⁴, Cinzia Mazzanti², Biagio Didona¹⁵, Giovanni Di Zenzo¹⁶; Cutaneous Immunology Group of SIDeMaST

Affiliations

¹ Molecular and Cell Biology Laboratory, IDI-IRCCS, Rome, Italy.
² First Dermatology Clinic, IDI-IRCCS, Rome, Italy.
³ Dermatology unit, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
⁴ Rare Diseases Unit, Section of Dermatology, Department of Health Sciences, USL Toscana Centro, European Reference Network-Skin Member, University of Florence, Florence, Italy.
⁵ Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, Università Degli Studi di Milano, Milan, Italy.
⁶ DiSSal, Dermatology Clinic, San Martino Polyclinic Hospital-IRCCS, University of Genoa, Genoa, Italy.
⁷ Dermatology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.
⁸ Institute of Dermatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università del Sacro Cuore, Rome, Italy.
⁹ Dermatologic Clinic of Terni, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
¹⁰ Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Italy.
¹¹ Pathology Unit, IDI-IRCCS, Rome, Italy.
¹² Laboratory of Cutaneous Physiopathology and Integrated Center for Metabolomics Research, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
¹³ Fifth Dermatology Clinic, IDI-IRCCS, Rome, Italy.
¹⁴ Clinical Epidemiology Unit, IDI-IRCCS, Rome, Italy.
¹⁵ Rare disease Unit, IDI-IRCCS, Rome, Italy.
¹⁶ Molecular and Cell Biology Laboratory, IDI-IRCCS, Rome, Italy. Electronic address: g.dizenzo@idi.it.

PMID: 35240229
DOI: 10.1016/j.jaad.2022.02.036

Multicenter Study

Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study

Adele Salemme et al. J Am Acad Dermatol. 2022 Jul.

. 2022 Jul;87(1):56-63.

doi: 10.1016/j.jaad.2022.02.036. Epub 2022 Mar 1.

Authors

Affiliations

¹ Molecular and Cell Biology Laboratory, IDI-IRCCS, Rome, Italy.
² First Dermatology Clinic, IDI-IRCCS, Rome, Italy.
³ Dermatology unit, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
⁴ Rare Diseases Unit, Section of Dermatology, Department of Health Sciences, USL Toscana Centro, European Reference Network-Skin Member, University of Florence, Florence, Italy.
⁵ Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, Università Degli Studi di Milano, Milan, Italy.
⁶ DiSSal, Dermatology Clinic, San Martino Polyclinic Hospital-IRCCS, University of Genoa, Genoa, Italy.
⁷ Dermatology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.
⁸ Institute of Dermatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università del Sacro Cuore, Rome, Italy.
⁹ Dermatologic Clinic of Terni, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
¹⁰ Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Italy.
¹¹ Pathology Unit, IDI-IRCCS, Rome, Italy.
¹² Laboratory of Cutaneous Physiopathology and Integrated Center for Metabolomics Research, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
¹³ Fifth Dermatology Clinic, IDI-IRCCS, Rome, Italy.
¹⁴ Clinical Epidemiology Unit, IDI-IRCCS, Rome, Italy.
¹⁵ Rare disease Unit, IDI-IRCCS, Rome, Italy.
¹⁶ Molecular and Cell Biology Laboratory, IDI-IRCCS, Rome, Italy. Electronic address: g.dizenzo@idi.it.

PMID: 35240229
DOI: 10.1016/j.jaad.2022.02.036

Abstract

Background: Recently, several case-control studies demonstrated an association between gliptins and bullous pemphigoid (BP) occurrence. However, data on the clinical and immunologic features of gliptin-associated bullous pemphigoid (GABP) are controversial.

Objective: This study aimed to clinically and immunologically characterize a large cohort of GABP patients to get an insight into the pathophysiology of this emerging drug-induced variant of BP.

Methods: Seventy-four GABP patients were prospectively enrolled and characterized from 9 different Italian dermatology units between 2013 and 2020.

Results: Our findings demonstrated the following in the GABP patients: (1) a noninflammatory phenotype, which is characterized by low amounts of circulating and skin-infiltrating eosinophils, is frequently found; (2) immunoglobulin (Ig)G, IgE, and IgA humoral responses to BP180 and BP230 antigens are reduced in frequency and titers compared with those in patients with idiopathic BP; (3) IgG reactivity targets multiple BP180 epitopes other than noncollagenous region 16A.

Limitations: A limitation of the study is that the control group did not comprise only type 2 diabetes mellitus patients with BP.

Conclusion: GABP patients show peculiar features of anti-BP180 and -BP230 humoral responses, laying the foundation for diagnostic improvements and getting novel insights into understanding the mechanism of BP onset.

Keywords: BP180; autoantibody; bullous pemphigoid; epitope; gliptin; humoral response.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest None disclosed.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study

Affiliations

Gliptin-associated bullous pemphigoid shows peculiar features of anti-BP180 and -BP230 humoral response: Results of a multicenter study

Authors

Affiliations

Abstract

Conflict of interest statement

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous